Department of Laboratory, Hospital 3201, Hanzhong, 723000 Shaanxi, China.
Department of Neurology, Hospital 302 Attached to Guizhou Aviation Group, Anshun, 561000 Guizhou, China.
Cardiovasc Ther. 2022 Oct 14;2022:3328574. doi: 10.1155/2022/3328574. eCollection 2022.
Ischemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in the inflammation response have been identified as diagnosing biomarkers of ischemic stroke. One of these is lipoprotein-associated phospholipase A (Lp-PLA), an enzyme that can hydrolyze circulating oxidized phospholipids, generating proinflammatory lysophosphatidylcholine and promoting the development of atherosclerosis. In the last two decades, a number of studies have revealed that both the concentration and the activity of Lp-PLA are independent biomarkers of ischemic stroke. The US Food and Drug Administration (FDA) has approved two tests to determine Lp-PLA mass and activity for predicting stroke. In this review, we summarize the biological properties of Lp-PLA, the detection sensitivity and limitations of Lp-PLA measurement, the clinical significance and association of Lp-PLA in ischemic stroke, and the prospects of therapeutic inhibition of Lp-PLA as an intervention and treatment.
缺血性脑卒中是由于大脑供血受阻而引起的,是全球范围内的主要致死病因。其主要病因是动脉粥样硬化,这是一种动脉疾病,其特征是脂肪物质斑块在动脉壁内部沉积。已有多种参与炎症反应的蛋白质被鉴定为缺血性脑卒中的诊断生物标志物。其中之一是脂蛋白相关磷脂酶 A(Lp-PLA),它是一种可以水解循环中氧化磷脂的酶,生成促炎的溶血磷脂酰胆碱,并促进动脉粥样硬化的发展。在过去的二十年中,多项研究表明,Lp-PLA 的浓度和活性都是缺血性脑卒中的独立生物标志物。美国食品和药物管理局(FDA)已批准了两项测试来确定 Lp-PLA 质量和活性,以预测中风。在这篇综述中,我们总结了 Lp-PLA 的生物学特性、Lp-PLA 检测的灵敏度和局限性、Lp-PLA 在缺血性脑卒中中的临床意义和相关性,以及作为一种干预和治疗方法抑制 Lp-PLA 的治疗前景。